Abstract
Inhalation challenge with methacholine is now a standardized procedure using a drug specifically approved for the purpose of determining the nature and extent of airways hyperreactivity. The methodology described involves the intermittent administration of graduated concentrations of methacholine by aerosol inhalation followed by routine spirometry after each incremental dose thereby enabling the construction of a dose response curve. The PD20FEV1, the provocation dose of agonist necessary for a 20% decrease in FEV1, is interpolated from the curve and is the accepted index of airways sensitivity. Clinically, the procedure has been widely used to implement the diagnosis of asthma in such atypical cases as when the physical exam and pulmonary function tests are equivocal. In such a setting, a positive test often justifies the use of therapeutic bronchodilators whereas a negative test would lead the examiner away from the alternative of hyperactive airways. Other applications include the evaluation of antigen sensitivity for diagnostic and research purposes including occupational asthma, epidemiology, and investigational drug trials.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 113-122 |
| Number of pages | 10 |
| Journal | New England and regional allergy proceedings |
| Volume | 9 |
| Issue number | 2 |
| State | Published - Mar 1988 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Inhalation challenge. / Rosenthal, Richard R.
In: New England and regional allergy proceedings, Vol. 9, No. 2, 03.1988, p. 113-122.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Inhalation challenge.
AU - Rosenthal, Richard R
PY - 1988/3
Y1 - 1988/3
N2 - Inhalation challenge with methacholine is now a standardized procedure using a drug specifically approved for the purpose of determining the nature and extent of airways hyperreactivity. The methodology described involves the intermittent administration of graduated concentrations of methacholine by aerosol inhalation followed by routine spirometry after each incremental dose thereby enabling the construction of a dose response curve. The PD20FEV1, the provocation dose of agonist necessary for a 20% decrease in FEV1, is interpolated from the curve and is the accepted index of airways sensitivity. Clinically, the procedure has been widely used to implement the diagnosis of asthma in such atypical cases as when the physical exam and pulmonary function tests are equivocal. In such a setting, a positive test often justifies the use of therapeutic bronchodilators whereas a negative test would lead the examiner away from the alternative of hyperactive airways. Other applications include the evaluation of antigen sensitivity for diagnostic and research purposes including occupational asthma, epidemiology, and investigational drug trials.
AB - Inhalation challenge with methacholine is now a standardized procedure using a drug specifically approved for the purpose of determining the nature and extent of airways hyperreactivity. The methodology described involves the intermittent administration of graduated concentrations of methacholine by aerosol inhalation followed by routine spirometry after each incremental dose thereby enabling the construction of a dose response curve. The PD20FEV1, the provocation dose of agonist necessary for a 20% decrease in FEV1, is interpolated from the curve and is the accepted index of airways sensitivity. Clinically, the procedure has been widely used to implement the diagnosis of asthma in such atypical cases as when the physical exam and pulmonary function tests are equivocal. In such a setting, a positive test often justifies the use of therapeutic bronchodilators whereas a negative test would lead the examiner away from the alternative of hyperactive airways. Other applications include the evaluation of antigen sensitivity for diagnostic and research purposes including occupational asthma, epidemiology, and investigational drug trials.
UR - http://www.scopus.com/inward/record.url?scp=0023971611&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023971611&partnerID=8YFLogxK
M3 - Article
C2 - 3292886
AN - SCOPUS:0023971611
VL - 9
SP - 113
EP - 122
JO - Allergy and Asthma Proceedings
JF - Allergy and Asthma Proceedings
SN - 1088-5412
IS - 2
ER -